WuXi STA and Antengene partner under MAH scheme

By Flora Southey contact

- Last updated on GMT

(Image: Getty/JavierHuras)
(Image: Getty/JavierHuras)

Related tags: China, Asia pacific, Wuxi

Antengene has selected CMO WuXi STA to develop and manufacture its mTOR inhibitor product ATG-008 for Chinese and Asia-Pacific markets.

According to the terms, Chinese contract development and manufacturing organisation (CDMO) STA Pharmaceutical (WuXi STA) – a subsidiary of WuXi AppTec – will provide process R&D and manufacturing services for Antengene’s oncology drugs.

The collaboration will focus on Antengene’s Phase II/III mTOR inhibitor candidate ATG-008, designed for the treatment of hepatitis B virus positive advanced hepatocellular carcinoma (HCC) patients, and extend to commercial-stage assets.

Antengene’s pipeline focuses on relapsed/refractory multiple myeloma, lymphomas and solid tumours, as well as colorectal and prostate cancers. Early-phase ATG-527 is being explored for anti-viral indications such as influenza, RSV (respiratory syncytial virus infection), and EB (Epstein Barr) viral-related diseases.

The partnership marks the first time the companies have collaborated, and will target Chinese and Asia-Pacific regions, a WuXi STA spokesperson told us.

According to Antengene CEO Jay Mei, “WuXi STA’s end-to-end CMC [chemistry, manufacturing, and controls] platform enables us to focus on our research and development, and to move our drug candidates from clinical-stage to commercialisation more efficiently. We look forward to a much broader collaboration in the near future.”

The agreement follows on from China’s 2016 Marketing Authorisation Holder (MAH) pilot programme​, which enables good manufacturing practice (GMP)-compliant third party manufacturers, in some provinces, to make pharmaceutical drug products for customers.

Last month​, China approved its first CMO-made new drug since the implementation of the MAH scheme – Ascletis’ viral hepatitis C treatment Ganovo – which had been made by WuXi STA.

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us

Products

View more

Webinars